The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Dry Powder Inhalation Medication Market Research Report 2025
Synopsis
Dry powder inhaler (DPI), also known as inhalation powder mist, refers to the solid micronized raw material drug alone or mixed with a suitable carrier, in the form of capsules, vesicles or multi-dose storage, using a specially made dry powder for inhalation A device in which the patient actively inhales aerosolized medication into the lungs. It has decades of research history abroad, and most of the drugs currently on the market are used to treat asthma and chronic obstructive pulmonary disease.
The global Dry Powder Inhalation Medication market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Dry Powder Inhalation Medication is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Dry Powder Inhalation Medication is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Dry Powder Inhalation Medication include Pharmaxis Ltd., AstraZeneca, GSK, Novartis, Gilead Sciences, Boehringer Ingelheim, ORION CORPORATION, Teva Pharmaceuticals and TFF Pharmaceuticals Inc., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Dry Powder Inhalation Medication, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dry Powder Inhalation Medication.
Report Scope
The Dry Powder Inhalation Medication market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Dry Powder Inhalation Medication market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Dry Powder Inhalation Medication manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pharmaxis Ltd.
AstraZeneca
GSK
Novartis
Gilead Sciences
Boehringer Ingelheim
ORION CORPORATION
Teva Pharmaceuticals
TFF Pharmaceuticals Inc.
Sunovion Pharmaceuticals
Pfizer
Eli Lilly and Company
Segment by Type
Single Dose
Multiple Doses
Storage Type
Segment by Application
Asthmatic
COPD
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Dry Powder Inhalation Medication manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Dry Powder Inhalation Medication in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Dry powder inhaler (DPI), also known as inhalation powder mist, refers to the solid micronized raw material drug alone or mixed with a suitable carrier, in the form of capsules, vesicles or multi-dose storage, using a specially made dry powder for inhalation A device in which the patient actively inhales aerosolized medication into the lungs. It has decades of research history abroad, and most of the drugs currently on the market are used to treat asthma and chronic obstructive pulmonary disease.
The global Dry Powder Inhalation Medication market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Dry Powder Inhalation Medication is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Dry Powder Inhalation Medication is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Dry Powder Inhalation Medication include Pharmaxis Ltd., AstraZeneca, GSK, Novartis, Gilead Sciences, Boehringer Ingelheim, ORION CORPORATION, Teva Pharmaceuticals and TFF Pharmaceuticals Inc., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Dry Powder Inhalation Medication, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dry Powder Inhalation Medication.
Report Scope
The Dry Powder Inhalation Medication market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Dry Powder Inhalation Medication market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Dry Powder Inhalation Medication manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pharmaxis Ltd.
AstraZeneca
GSK
Novartis
Gilead Sciences
Boehringer Ingelheim
ORION CORPORATION
Teva Pharmaceuticals
TFF Pharmaceuticals Inc.
Sunovion Pharmaceuticals
Pfizer
Eli Lilly and Company
Segment by Type
Single Dose
Multiple Doses
Storage Type
Segment by Application
Asthmatic
COPD
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Dry Powder Inhalation Medication manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Dry Powder Inhalation Medication in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Dry Powder Inhalation Medication Market Overview
1.1 Product Overview and Scope of Dry Powder Inhalation Medication
1.2 Dry Powder Inhalation Medication Segment by Type
1.2.1 Global Dry Powder Inhalation Medication Market Value Comparison by Type (2024-2030)
1.2.2 Single Dose
1.2.3 Multiple Doses
1.2.4 Storage Type
1.3 Dry Powder Inhalation Medication Segment by Application
1.3.1 Global Dry Powder Inhalation Medication Market Value by Application: (2024-2030)
1.3.2 Asthmatic
1.3.3 COPD
1.3.4 Other
1.4 Global Dry Powder Inhalation Medication Market Size Estimates and Forecasts
1.4.1 Global Dry Powder Inhalation Medication Revenue 2019-2030
1.4.2 Global Dry Powder Inhalation Medication Sales 2019-2030
1.4.3 Global Dry Powder Inhalation Medication Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Dry Powder Inhalation Medication Market Competition by Manufacturers
2.1 Global Dry Powder Inhalation Medication Sales Market Share by Manufacturers (2019-2024)
2.2 Global Dry Powder Inhalation Medication Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Dry Powder Inhalation Medication Average Price by Manufacturers (2019-2024)
2.4 Global Dry Powder Inhalation Medication Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Dry Powder Inhalation Medication, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Dry Powder Inhalation Medication, Product Type & Application
2.7 Dry Powder Inhalation Medication Market Competitive Situation and Trends
2.7.1 Dry Powder Inhalation Medication Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Dry Powder Inhalation Medication Players Market Share by Revenue
2.7.3 Global Dry Powder Inhalation Medication Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Dry Powder Inhalation Medication Retrospective Market Scenario by Region
3.1 Global Dry Powder Inhalation Medication Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Dry Powder Inhalation Medication Global Dry Powder Inhalation Medication Sales by Region: 2019-2030
3.2.1 Global Dry Powder Inhalation Medication Sales by Region: 2019-2024
3.2.2 Global Dry Powder Inhalation Medication Sales by Region: 2025-2030
3.3 Global Dry Powder Inhalation Medication Global Dry Powder Inhalation Medication Revenue by Region: 2019-2030
3.3.1 Global Dry Powder Inhalation Medication Revenue by Region: 2019-2024
3.3.2 Global Dry Powder Inhalation Medication Revenue by Region: 2025-2030
3.4 North America Dry Powder Inhalation Medication Market Facts & Figures by Country
3.4.1 North America Dry Powder Inhalation Medication Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Dry Powder Inhalation Medication Sales by Country (2019-2030)
3.4.3 North America Dry Powder Inhalation Medication Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Dry Powder Inhalation Medication Market Facts & Figures by Country
3.5.1 Europe Dry Powder Inhalation Medication Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Dry Powder Inhalation Medication Sales by Country (2019-2030)
3.5.3 Europe Dry Powder Inhalation Medication Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Netherlands
3.6 Asia Pacific Dry Powder Inhalation Medication Market Facts & Figures by Country
3.6.1 Asia Pacific Dry Powder Inhalation Medication Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Dry Powder Inhalation Medication Sales by Country (2019-2030)
3.6.3 Asia Pacific Dry Powder Inhalation Medication Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Southeast Asia
3.6.9 China Taiwan
3.6.10 Australia
3.7 Latin America Dry Powder Inhalation Medication Market Facts & Figures by Country
3.7.1 Latin America Dry Powder Inhalation Medication Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Dry Powder Inhalation Medication Sales by Country (2019-2030)
3.7.3 Latin America Dry Powder Inhalation Medication Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Dry Powder Inhalation Medication Market Facts & Figures by Country
3.8.1 Middle East and Africa Dry Powder Inhalation Medication Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Dry Powder Inhalation Medication Sales by Country (2019-2030)
3.8.3 Middle East and Africa Dry Powder Inhalation Medication Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Dry Powder Inhalation Medication Sales by Type (2019-2030)
4.1.1 Global Dry Powder Inhalation Medication Sales by Type (2019-2024)
4.1.2 Global Dry Powder Inhalation Medication Sales by Type (2025-2030)
4.1.3 Global Dry Powder Inhalation Medication Sales Market Share by Type (2019-2030)
4.2 Global Dry Powder Inhalation Medication Revenue by Type (2019-2030)
4.2.1 Global Dry Powder Inhalation Medication Revenue by Type (2019-2024)
4.2.2 Global Dry Powder Inhalation Medication Revenue by Type (2025-2030)
4.2.3 Global Dry Powder Inhalation Medication Revenue Market Share by Type (2019-2030)
4.3 Global Dry Powder Inhalation Medication Price by Type (2019-2030)
5 Segment by Application
5.1 Global Dry Powder Inhalation Medication Sales by Application (2019-2030)
5.1.1 Global Dry Powder Inhalation Medication Sales by Application (2019-2024)
5.1.2 Global Dry Powder Inhalation Medication Sales by Application (2025-2030)
5.1.3 Global Dry Powder Inhalation Medication Sales Market Share by Application (2019-2030)
5.2 Global Dry Powder Inhalation Medication Revenue by Application (2019-2030)
5.2.1 Global Dry Powder Inhalation Medication Revenue by Application (2019-2024)
5.2.2 Global Dry Powder Inhalation Medication Revenue by Application (2025-2030)
5.2.3 Global Dry Powder Inhalation Medication Revenue Market Share by Application (2019-2030)
5.3 Global Dry Powder Inhalation Medication Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Pharmaxis Ltd.
6.1.1 Pharmaxis Ltd. Corporation Information
6.1.2 Pharmaxis Ltd. Description and Business Overview
6.1.3 Pharmaxis Ltd. Dry Powder Inhalation Medication Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pharmaxis Ltd. Dry Powder Inhalation Medication Product Portfolio
6.1.5 Pharmaxis Ltd. Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Dry Powder Inhalation Medication Sales, Revenue and Gross Margin (2019-2024)
6.2.4 AstraZeneca Dry Powder Inhalation Medication Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 GSK
6.3.1 GSK Corporation Information
6.3.2 GSK Description and Business Overview
6.3.3 GSK Dry Powder Inhalation Medication Sales, Revenue and Gross Margin (2019-2024)
6.3.4 GSK Dry Powder Inhalation Medication Product Portfolio
6.3.5 GSK Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Corporation Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Dry Powder Inhalation Medication Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novartis Dry Powder Inhalation Medication Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Gilead Sciences
6.5.1 Gilead Sciences Corporation Information
6.5.2 Gilead Sciences Description and Business Overview
6.5.3 Gilead Sciences Dry Powder Inhalation Medication Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Gilead Sciences Dry Powder Inhalation Medication Product Portfolio
6.5.5 Gilead Sciences Recent Developments/Updates
6.6 Boehringer Ingelheim
6.6.1 Boehringer Ingelheim Corporation Information
6.6.2 Boehringer Ingelheim Description and Business Overview
6.6.3 Boehringer Ingelheim Dry Powder Inhalation Medication Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Boehringer Ingelheim Dry Powder Inhalation Medication Product Portfolio
6.6.5 Boehringer Ingelheim Recent Developments/Updates
6.7 ORION CORPORATION
6.6.1 ORION CORPORATION Corporation Information
6.6.2 ORION CORPORATION Description and Business Overview
6.6.3 ORION CORPORATION Dry Powder Inhalation Medication Sales, Revenue and Gross Margin (2019-2024)
6.4.4 ORION CORPORATION Dry Powder Inhalation Medication Product Portfolio
6.7.5 ORION CORPORATION Recent Developments/Updates
6.8 Teva Pharmaceuticals
6.8.1 Teva Pharmaceuticals Corporation Information
6.8.2 Teva Pharmaceuticals Description and Business Overview
6.8.3 Teva Pharmaceuticals Dry Powder Inhalation Medication Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Teva Pharmaceuticals Dry Powder Inhalation Medication Product Portfolio
6.8.5 Teva Pharmaceuticals Recent Developments/Updates
6.9 TFF Pharmaceuticals Inc.
6.9.1 TFF Pharmaceuticals Inc. Corporation Information
6.9.2 TFF Pharmaceuticals Inc. Description and Business Overview
6.9.3 TFF Pharmaceuticals Inc. Dry Powder Inhalation Medication Sales, Revenue and Gross Margin (2019-2024)
6.9.4 TFF Pharmaceuticals Inc. Dry Powder Inhalation Medication Product Portfolio
6.9.5 TFF Pharmaceuticals Inc. Recent Developments/Updates
6.10 Sunovion Pharmaceuticals
6.10.1 Sunovion Pharmaceuticals Corporation Information
6.10.2 Sunovion Pharmaceuticals Description and Business Overview
6.10.3 Sunovion Pharmaceuticals Dry Powder Inhalation Medication Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Sunovion Pharmaceuticals Dry Powder Inhalation Medication Product Portfolio
6.10.5 Sunovion Pharmaceuticals Recent Developments/Updates
6.11 Pfizer
6.11.1 Pfizer Corporation Information
6.11.2 Pfizer Dry Powder Inhalation Medication Description and Business Overview
6.11.3 Pfizer Dry Powder Inhalation Medication Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Pfizer Dry Powder Inhalation Medication Product Portfolio
6.11.5 Pfizer Recent Developments/Updates
6.12 Eli Lilly and Company
6.12.1 Eli Lilly and Company Corporation Information
6.12.2 Eli Lilly and Company Dry Powder Inhalation Medication Description and Business Overview
6.12.3 Eli Lilly and Company Dry Powder Inhalation Medication Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Eli Lilly and Company Dry Powder Inhalation Medication Product Portfolio
6.12.5 Eli Lilly and Company Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Dry Powder Inhalation Medication Industry Chain Analysis
7.2 Dry Powder Inhalation Medication Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Dry Powder Inhalation Medication Production Mode & Process
7.4 Dry Powder Inhalation Medication Sales and Marketing
7.4.1 Dry Powder Inhalation Medication Sales Channels
7.4.2 Dry Powder Inhalation Medication Distributors
7.5 Dry Powder Inhalation Medication Customers
8 Dry Powder Inhalation Medication Market Dynamics
8.1 Dry Powder Inhalation Medication Industry Trends
8.2 Dry Powder Inhalation Medication Market Drivers
8.3 Dry Powder Inhalation Medication Market Challenges
8.4 Dry Powder Inhalation Medication Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Dry Powder Inhalation Medication Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Dry Powder Inhalation Medication Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Dry Powder Inhalation Medication Market Competitive Situation by Manufacturers in 2023
Table 4. Global Dry Powder Inhalation Medication Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Dry Powder Inhalation Medication Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Dry Powder Inhalation Medication Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Dry Powder Inhalation Medication Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Dry Powder Inhalation Medication Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Dry Powder Inhalation Medication, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Dry Powder Inhalation Medication, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Dry Powder Inhalation Medication, Product Type & Application
Table 12. Global Key Manufacturers of Dry Powder Inhalation Medication, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Dry Powder Inhalation Medication by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dry Powder Inhalation Medication as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Dry Powder Inhalation Medication Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Dry Powder Inhalation Medication Sales by Region (2019-2024) & (K Units)
Table 18. Global Dry Powder Inhalation Medication Sales Market Share by Region (2019-2024)
Table 19. Global Dry Powder Inhalation Medication Sales by Region (2025-2030) & (K Units)
Table 20. Global Dry Powder Inhalation Medication Sales Market Share by Region (2025-2030)
Table 21. Global Dry Powder Inhalation Medication Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Dry Powder Inhalation Medication Revenue Market Share by Region (2019-2024)
Table 23. Global Dry Powder Inhalation Medication Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Dry Powder Inhalation Medication Revenue Market Share by Region (2025-2030)
Table 25. North America Dry Powder Inhalation Medication Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Dry Powder Inhalation Medication Sales by Country (2019-2024) & (K Units)
Table 27. North America Dry Powder Inhalation Medication Sales by Country (2025-2030) & (K Units)
Table 28. North America Dry Powder Inhalation Medication Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Dry Powder Inhalation Medication Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Dry Powder Inhalation Medication Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Dry Powder Inhalation Medication Sales by Country (2019-2024) & (K Units)
Table 32. Europe Dry Powder Inhalation Medication Sales by Country (2025-2030) & (K Units)
Table 33. Europe Dry Powder Inhalation Medication Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Dry Powder Inhalation Medication Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Dry Powder Inhalation Medication Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Dry Powder Inhalation Medication Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Dry Powder Inhalation Medication Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Dry Powder Inhalation Medication Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Dry Powder Inhalation Medication Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Dry Powder Inhalation Medication Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Dry Powder Inhalation Medication Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Dry Powder Inhalation Medication Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Dry Powder Inhalation Medication Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Dry Powder Inhalation Medication Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Dry Powder Inhalation Medication Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Dry Powder Inhalation Medication Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Dry Powder Inhalation Medication Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Dry Powder Inhalation Medication Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Dry Powder Inhalation Medication Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Dry Powder Inhalation Medication Sales (K Units) by Type (2019-2024)
Table 51. Global Dry Powder Inhalation Medication Sales (K Units) by Type (2025-2030)
Table 52. Global Dry Powder Inhalation Medication Sales Market Share by Type (2019-2024)
Table 53. Global Dry Powder Inhalation Medication Sales Market Share by Type (2025-2030)
Table 54. Global Dry Powder Inhalation Medication Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Dry Powder Inhalation Medication Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Dry Powder Inhalation Medication Revenue Market Share by Type (2019-2024)
Table 57. Global Dry Powder Inhalation Medication Revenue Market Share by Type (2025-2030)
Table 58. Global Dry Powder Inhalation Medication Price (US$/Unit) by Type (2019-2024)
Table 59. Global Dry Powder Inhalation Medication Price (US$/Unit) by Type (2025-2030)
Table 60. Global Dry Powder Inhalation Medication Sales (K Units) by Application (2019-2024)
Table 61. Global Dry Powder Inhalation Medication Sales (K Units) by Application (2025-2030)
Table 62. Global Dry Powder Inhalation Medication Sales Market Share by Application (2019-2024)
Table 63. Global Dry Powder Inhalation Medication Sales Market Share by Application (2025-2030)
Table 64. Global Dry Powder Inhalation Medication Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Dry Powder Inhalation Medication Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Dry Powder Inhalation Medication Revenue Market Share by Application (2019-2024)
Table 67. Global Dry Powder Inhalation Medication Revenue Market Share by Application (2025-2030)
Table 68. Global Dry Powder Inhalation Medication Price (US$/Unit) by Application (2019-2024)
Table 69. Global Dry Powder Inhalation Medication Price (US$/Unit) by Application (2025-2030)
Table 70. Pharmaxis Ltd. Corporation Information
Table 71. Pharmaxis Ltd. Description and Business Overview
Table 72. Pharmaxis Ltd. Dry Powder Inhalation Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Pharmaxis Ltd. Dry Powder Inhalation Medication Product
Table 74. Pharmaxis Ltd. Recent Developments/Updates
Table 75. AstraZeneca Corporation Information
Table 76. AstraZeneca Description and Business Overview
Table 77. AstraZeneca Dry Powder Inhalation Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. AstraZeneca Dry Powder Inhalation Medication Product
Table 79. AstraZeneca Recent Developments/Updates
Table 80. GSK Corporation Information
Table 81. GSK Description and Business Overview
Table 82. GSK Dry Powder Inhalation Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. GSK Dry Powder Inhalation Medication Product
Table 84. GSK Recent Developments/Updates
Table 85. Novartis Corporation Information
Table 86. Novartis Description and Business Overview
Table 87. Novartis Dry Powder Inhalation Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Novartis Dry Powder Inhalation Medication Product
Table 89. Novartis Recent Developments/Updates
Table 90. Gilead Sciences Corporation Information
Table 91. Gilead Sciences Description and Business Overview
Table 92. Gilead Sciences Dry Powder Inhalation Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Gilead Sciences Dry Powder Inhalation Medication Product
Table 94. Gilead Sciences Recent Developments/Updates
Table 95. Boehringer Ingelheim Corporation Information
Table 96. Boehringer Ingelheim Description and Business Overview
Table 97. Boehringer Ingelheim Dry Powder Inhalation Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Boehringer Ingelheim Dry Powder Inhalation Medication Product
Table 99. Boehringer Ingelheim Recent Developments/Updates
Table 100. ORION CORPORATION Corporation Information
Table 101. ORION CORPORATION Description and Business Overview
Table 102. ORION CORPORATION Dry Powder Inhalation Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. ORION CORPORATION Dry Powder Inhalation Medication Product
Table 104. ORION CORPORATION Recent Developments/Updates
Table 105. Teva Pharmaceuticals Corporation Information
Table 106. Teva Pharmaceuticals Description and Business Overview
Table 107. Teva Pharmaceuticals Dry Powder Inhalation Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Teva Pharmaceuticals Dry Powder Inhalation Medication Product
Table 109. Teva Pharmaceuticals Recent Developments/Updates
Table 110. TFF Pharmaceuticals Inc. Corporation Information
Table 111. TFF Pharmaceuticals Inc. Description and Business Overview
Table 112. TFF Pharmaceuticals Inc. Dry Powder Inhalation Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. TFF Pharmaceuticals Inc. Dry Powder Inhalation Medication Product
Table 114. TFF Pharmaceuticals Inc. Recent Developments/Updates
Table 115. Sunovion Pharmaceuticals Corporation Information
Table 116. Sunovion Pharmaceuticals Description and Business Overview
Table 117. Sunovion Pharmaceuticals Dry Powder Inhalation Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Sunovion Pharmaceuticals Dry Powder Inhalation Medication Product
Table 119. Sunovion Pharmaceuticals Recent Developments/Updates
Table 120. Pfizer Corporation Information
Table 121. Pfizer Description and Business Overview
Table 122. Pfizer Dry Powder Inhalation Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Pfizer Dry Powder Inhalation Medication Product
Table 124. Pfizer Recent Developments/Updates
Table 125. Eli Lilly and Company Corporation Information
Table 126. Eli Lilly and Company Description and Business Overview
Table 127. Eli Lilly and Company Dry Powder Inhalation Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Eli Lilly and Company Dry Powder Inhalation Medication Product
Table 129. Eli Lilly and Company Recent Developments/Updates
Table 130. Key Raw Materials Lists
Table 131. Raw Materials Key Suppliers Lists
Table 132. Dry Powder Inhalation Medication Distributors List
Table 133. Dry Powder Inhalation Medication Customers List
Table 134. Dry Powder Inhalation Medication Market Trends
Table 135. Dry Powder Inhalation Medication Market Drivers
Table 136. Dry Powder Inhalation Medication Market Challenges
Table 137. Dry Powder Inhalation Medication Market Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Dry Powder Inhalation Medication
Figure 2. Global Dry Powder Inhalation Medication Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Dry Powder Inhalation Medication Market Share by Type in 2023 & 2030
Figure 4. Single Dose Product Picture
Figure 5. Multiple Doses Product Picture
Figure 6. Storage Type Product Picture
Figure 7. Global Dry Powder Inhalation Medication Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Dry Powder Inhalation Medication Market Share by Application in 2023 & 2030
Figure 9. Asthmatic
Figure 10. COPD
Figure 11. Other
Figure 12. Global Dry Powder Inhalation Medication Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Dry Powder Inhalation Medication Market Size (2019-2030) & (US$ Million)
Figure 14. Global Dry Powder Inhalation Medication Sales (2019-2030) & (K Units)
Figure 15. Global Dry Powder Inhalation Medication Average Price (US$/Unit) & (2019-2030)
Figure 16. Dry Powder Inhalation Medication Report Years Considered
Figure 17. Dry Powder Inhalation Medication Sales Share by Manufacturers in 2023
Figure 18. Global Dry Powder Inhalation Medication Revenue Share by Manufacturers in 2023
Figure 19. The Global 5 and 10 Largest Dry Powder Inhalation Medication Players: Market Share by Revenue in 2023
Figure 20. Dry Powder Inhalation Medication Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 21. Global Dry Powder Inhalation Medication Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 22. North America Dry Powder Inhalation Medication Sales Market Share by Country (2019-2030)
Figure 23. North America Dry Powder Inhalation Medication Revenue Market Share by Country (2019-2030)
Figure 24. United States Dry Powder Inhalation Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Canada Dry Powder Inhalation Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Europe Dry Powder Inhalation Medication Sales Market Share by Country (2019-2030)
Figure 27. Europe Dry Powder Inhalation Medication Revenue Market Share by Country (2019-2030)
Figure 28. Germany Dry Powder Inhalation Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. France Dry Powder Inhalation Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. U.K. Dry Powder Inhalation Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Italy Dry Powder Inhalation Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Netherlands Dry Powder Inhalation Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Asia Pacific Dry Powder Inhalation Medication Sales Market Share by Region (2019-2030)
Figure 34. Asia Pacific Dry Powder Inhalation Medication Revenue Market Share by Region (2019-2030)
Figure 35. China Dry Powder Inhalation Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Japan Dry Powder Inhalation Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. South Korea Dry Powder Inhalation Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. India Dry Powder Inhalation Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Southeast Asia Dry Powder Inhalation Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. China Taiwan Dry Powder Inhalation Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Australia Dry Powder Inhalation Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Latin America Dry Powder Inhalation Medication Sales Market Share by Country (2019-2030)
Figure 43. Latin America Dry Powder Inhalation Medication Revenue Market Share by Country (2019-2030)
Figure 44. Mexico Dry Powder Inhalation Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Brazil Dry Powder Inhalation Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Argentina Dry Powder Inhalation Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Colombia Dry Powder Inhalation Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Dry Powder Inhalation Medication Sales Market Share by Country (2019-2030)
Figure 49. Middle East & Africa Dry Powder Inhalation Medication Revenue Market Share by Country (2019-2030)
Figure 50. Turkey Dry Powder Inhalation Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia Dry Powder Inhalation Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. UAE Dry Powder Inhalation Medication Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Global Sales Market Share of Dry Powder Inhalation Medication by Type (2019-2030)
Figure 54. Global Revenue Market Share of Dry Powder Inhalation Medication by Type (2019-2030)
Figure 55. Global Dry Powder Inhalation Medication Price (US$/Unit) by Type (2019-2030)
Figure 56. Global Sales Market Share of Dry Powder Inhalation Medication by Application (2019-2030)
Figure 57. Global Revenue Market Share of Dry Powder Inhalation Medication by Application (2019-2030)
Figure 58. Global Dry Powder Inhalation Medication Price (US$/Unit) by Application (2019-2030)
Figure 59. Dry Powder Inhalation Medication Value Chain
Figure 60. Dry Powder Inhalation Medication Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
